DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

DexCom Inc. closed 52.68% below its 52-week high of $141.25, which the company reached on April 11th.

Mizuho analyst Anthony Petrone initiated coverage of DexCom (DXCM) with an Outperform rating and $85 price target The firm cites its positive ...

Global pharma and MedTech stocks rebound as U.S. President Donald Trump issues a 90-day pause on reciprocal tariffs for all ...

Shares of DexCom Inc. DXCM slipped 1.53% to $60.69 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.57% to 4,982.77 and Dow ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price ...

O Shaughnessy Asset Management LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 16.9% during the fourth quarter, according to its most recent filing with the SEC. The ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest ...

Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...

Despite intensive medtech industry lobbying to secure a carve-out from the Trump administration’s expansive tariffs on all ...